DNA Folding Goes Wrong in Alzheimer's Brain Cells, Study Finds

The three-dimensional architecture of DNA is disrupted inside brain cells affected by Alzheimer's disease, altering which genes are switched on. The finding describes a layer of the disease that sits between genetics and symptoms, and that had not been well mapped.

Why the shape of DNA matters

Two metres of DNA fit inside each cell nucleus, and how it is folded is not incidental. Genes are controlled in part by physical proximity: a regulatory sequence can sit a long way from the gene it controls along the strand and be brought against it by the way the strand loops. Change the folding and you change the wiring, without changing a single letter of the sequence.

What was found

In neurons from Alzheimer's-affected brains, that architecture was measurably altered compared with unaffected tissue, and the changes corresponded to differences in which genes were active. This is a different kind of explanation from the one the field has spent decades on. The amyloid and tau hypotheses describe proteins accumulating; this describes the control system of the cell being reorganised.

Where it fits

It does not replace the existing account so much as sit alongside it, and one of the open questions is the order of events. Disrupted folding could contribute to the disease process, or it could be a consequence of a cell already under stress from protein aggregates, inflammation and metabolic failure. Tissue examined after death shows the end state and is poorly suited to establishing sequence.

Why it is still useful

Genome-wide studies have identified many Alzheimer's risk variants that lie outside genes, in regions whose function is regulatory. A map of how the genome is folded in affected neurons is exactly what is needed to work out what those variants are actually doing -- and regulatory mechanisms are, in principle, more tractable targets than protein aggregates that have already formed.

What it means for patients now

Nothing directly. The treatments available today are the anti-amyloid antibodies, which slow decline modestly in early disease and carry real risks, and the symptomatic drugs that have been in use for years. The evidence on modifiable risk -- blood pressure, hearing loss, physical activity, smoking, education, social contact -- remains the most actionable thing in the field.

Bottom line

A new layer of the disease described, and an argument for looking at gene regulation rather than only at the proteins.